A recent landmark study, published in The Lancet Child & Adolescent Health, provides the first systematic evaluation of late effects experienced by survivors of high-risk neuroblastoma who were treated with modern therapeutic regimens that include stem cell transplantation and immunotherapy. Conducted by a consortium of the Children’s Oncology Group (COG) across 88 hospitals in North America, New Zealand, and Australia, the cohort study enrolled 375 survivors diagnosed from 2000 onward. Participants were aged between 5 and 50 at enrollment, reflecting a broad age spectrum to assess both pediatric and adult survivors’ long-term health sequelae.

One of the most striking findings from the study was the predominance of clinically significant hearing loss among survivors. Of the 327 individuals assessed, 72 percent exhibited moderate to severe hearing impairment. This sensory deficit is primarily attributed to the ototoxic chemotherapeutic agents routinely used in neuroblastoma treatment, such as platinum-based compounds. The implications of hearing loss extend beyond the immediate sensory deficit; it can drastically affect educational outcomes, communication skills, and overall quality of life. Early identification and intervention are crucial to mitigating these downstream impacts.

Beyond auditory complications, the study highlights profound challenges in physical growth and nutritional status. Approximately one-quarter of the 360 participants experienced growth failure, while more than half of the 373 survivors assessed were clinically underweight. These findings are clinically significant, as impaired growth trajectories and chronic undernutrition can represent hallmarks of accelerated biological aging processes. Children who survive high-intensity cancer therapies often manifest phenotypes resembling premature aging, which predisposes them to a myriad of chronic health conditions typically associated with older adults, such as cardiovascular disease, metabolic syndrome, and reduced bone density.

Pulmonary function also emerged as an area of concern, with restrictive lung disease identified in 8 percent of 207 survivors tested. This respiratory compromise may result from cumulative pulmonary toxicity due to chemotherapy, radiation, or complications from stem cell transplantation, including pulmonary fibrosis or chronic graft-versus-host disease. Such pulmonary limitations can negatively affect exercise capacity, respiratory reserve, and overall fitness, thereby imposing additional barriers to a normal, active lifestyle.

Crucially, the study delineated differential late effect risks based on treatment modalities. Survivors exposed to multiple stem cell transplants exhibited a heightened risk of growth failure and restrictive lung disease compared to those who underwent a single transplant. This dose-response relationship underscores the cumulative toxicities inherent in repeated high-dose therapies, necessitating risk-adjusted surveillance protocols. Conversely, the addition of immunotherapy, often heralded for its targeted mechanisms and improved tolerability, was not associated with an exacerbation of late sequelae, suggesting a favorable safety profile in the context of long-term survivorship.

The aggregation of these late effects is clinically impactful; the majority of survivors endured two or more significant late complications. Importantly, longitudinal follow-up demonstrated that the prevalence of these late effects escalates with increased survivorship duration, emphasizing the critical need for lifelong surveillance and supportive care strategies. This growing population of survivors represents an emerging demographic with complex, multifaceted health care requirements, challenging existing survivorship care frameworks.

Lead author Dr. Tara Henderson emphasized the transformative nature of this research, highlighting its role in reshaping clinical guidelines and informing future therapeutic trial designs. By elucidating the nuanced long-term risks associated with contemporary neuroblastoma treatments, clinicians can better balance efficacy and toxicity. Implementing tailored surveillance—such as routine audiological assessments, nutritional monitoring, and pulmonary function testing—can facilitate early detection and intervention, ultimately improving health outcomes and life quality.

Moreover, these data catalyze broader discussions about the biology of accelerated aging in cancer survivors. The interplay between intensive chemotherapeutic exposure, stem cell transplantation, and the host’s biological response likely contributes to premature organ system decline. This biological insight advocates for investment in novel therapeutic approaches that minimize long-term toxicity and the development of adjunctive interventions aimed at mitigating aging phenotypes post-cancer therapy.

The study’s influence extends beyond clinical care to research paradigms. By incorporating these survivorship data into clinical trial designs, researchers can integrate endpoints that account for long-term quality of life and late effects, not solely immediate oncologic outcomes. This comprehensive approach aligns with the evolving ethos of pediatric oncology that values survivorship as a continuum beginning at diagnosis and extending lifelong.

Funding for this pivotal research was provided by prominent organizations including the Children’s Oncology Group National Clinical Trials Network (NCTN) Statistics and Data Center, NCTN Operations Center, the St Baldrick’s Foundation Consortium, the National Cancer Institute Community Oncology Research Program, and the Dana-Farber Cancer Institute Neuroblastoma Research Fund. Their support underscores a multidisciplinary commitment to advancing neuroblastoma survivorship science.

Ann & Robert H. Lurie Children’s Hospital of Chicago, an institution renowned for pediatric clinical care and research, facilitated this study. Their focus on integrating clinical practice with cutting-edge research through the Stanley Manne Children’s Research Institute exemplifies the translational mission to transform pediatric oncology outcomes. As a designated pediatric training site for Northwestern University Feinberg School of Medicine, Lurie Children’s also embodies the educational environment nurturing the next generation of clinician-scientists addressing these complex survivorship issues.

In summary, the landmark study published in The Lancet Child & Adolescent Health offers unprecedented insights into the long-term morbidities faced by survivors of high-risk neuroblastoma treated with modern regimens. It reveals a high burden of hearing loss, growth impairment, undernutrition, and pulmonary dysfunction, with treatment intensity correlating to morbidity severity. Importantly, immunotherapy does not appear to add to these late effects, highlighting its potential as a safer adjunct. These findings mandate a paradigm shift in survivorship care encompassing vigilant, individualized follow-up to identify and manage late effects, aiming to optimize the lifelong health trajectories of neuroblastoma survivors.

Subject of Research: Long-term late effects in survivors of high-risk neuroblastoma treated with modern therapies including stem cell transplantation and immunotherapy

Article Title: [Not explicitly provided in the source text]

News Publication Date: [Not explicitly provided in the source text]

Web References:

• The Lancet Child & Adolescent Health: https://www.sciencedirect.com/science/article/abs/pii/S235246422500241X?via%3Dihub
• DOI link: http://dx.doi.org/10.1016/S2352-4642(25)00241-X

Keywords: Neuroblastoma, Cancer treatments, Stem cell therapy, Immunotherapy

Historically, the focus on second cancer risk has heavily emphasized the adverse late effects of treatments such as radiation and chemotherapy. While it has long been appreciated that exposure to ionizing radiation elevates cancer risk, this study contextualizes radiation as the most significant contributor, responsible for approximately 40% or more of the total risk burden for secondary cancers. The findings reaffirm concerns about radiation-induced oncogenesis and underscore ongoing clinical efforts to minimize radiation doses or eliminate radiation therapy when feasible, leveraging advances in targeted treatments that reduce collateral tissue damage.

Beyond radiation, the role of chemotherapy in second cancer risk emerges as more heterogeneous and dependent on the specific cancer subtype. The research demonstrates that chemotherapeutic agents contribute between 8% and 35% of the risk for subsequent malignancies. This variability reflects the diverse mechanisms by which different chemotherapy drugs may induce mutagenesis or impair DNA repair processes, which are intricately linked to oncogenesis years after treatment completion. While chemotherapy’s late effects have been documented extensively, their relative contribution compared to other factors has been less clear until now.

Perhaps the most striking revelation of this study lies in the elucidation of genetic factors influencing second cancer risk. Employing polygenic risk scoring (PRS)—a method that aggregates the effects of hundreds of common genetic variants associated with cancer susceptibility in the general population—investigators quantified the impact of inherited genetic predisposition on the development of subsequent neoplasms. Their results indicate that, contingent on cancer type, polygenic risk scores account for 5% to 37% of secondary cancer risk. This degree of influence rivals or in some cancers exceeds the contribution made by chemotherapy, challenging longstanding assumptions within pediatric oncology that genetics played a subordinate role.

These findings elevate the potential utility of genetic risk profiling in clinical survivorship care. Although polygenic risk scores have historically exhibited limited precision for predicting disease in general populations, their predictive value may be notably enhanced in childhood cancer survivors due to the interaction between inherited vulnerabilities and past therapeutic exposures. Tailoring surveillance protocols and preventive strategies according to individualized genetic risk profiles, combined with treatment histories, could herald a new era of personalized survivorship management aimed at early detection and prevention of secondary malignancies.

Intriguingly, lifestyle factors such as diet and physical activity, often lauded for their cancer-preventive potential in the general population, appeared to contribute minimally—only 1% to 6%—to second cancer risk within this cohort. It is important, however, to contextualize this finding within the demographics of the study participants, most of whom were in their twenties and thirties, an age range that may be too early to fully manifest lifestyle-related carcinogenic influences. Nevertheless, the importance of healthy behaviors remains undiminished for mitigating other late effects of childhood cancer treatment, including cardiovascular disease and metabolic disorders.

The study’s comprehensive dataset, encompassing genetic sequencing of over 12,000 survivors and detailed treatment exposure metrics, is unmatched in scope and depth in North America. Such a robust cohort enabled the application of advanced epidemiological models to parse the relative influences of diverse risk factors with unprecedented granularity. Co-author Dr. Gregory Armstrong emphasized that the synergy of the St. Jude LIFE and CCSS cohorts catalyzed breakthroughs not otherwise possible, highlighting the indispensable value of long-term, multi-institutional survivor registries for advancing precision medicine.

Clinically, these findings necessitate a paradigm shift. Past clinical guidelines for secondary cancer surveillance predominantly focused on the intensity and modality of prior cancer therapies. Now, incorporating genetic predisposition offers a more nuanced risk stratification framework. Patients harboring strong genetic susceptibilities could benefit from more rigorous and frequent monitoring, potentially enabling the earlier interception of secondary tumors when treatment efficacy is maximized. Conversely, survivors with lower combined risk profiles may avoid unnecessary screening burdens, optimizing resource allocation and minimizing patient anxiety.

Moreover, empowering survivors with knowledge of their personalized risk profiles could foster proactive engagement with healthcare providers and reinforce adherence to recommended screening regimens. This democratization of genetic and treatment exposure information aligns with the broader movement towards patient-centered care and shared decision-making, elements increasingly regarded as pillars of effective long-term survivorship programs.

The research team, led by first author Achal Neupane alongside experts including Siddhant Taneja, Jennifer French, and Yutaka Yasui, performed rigorous statistical analyses encompassing genetic variant testing, polygenic scoring, and epidemiologic modeling. Their interdisciplinary approach, drawing from genomics, oncology, and biostatistics, exemplifies how integrating multidimensional data sources can illuminate complex health outcomes.

Support for this landmark project was provided by multiple National Cancer Institute grants and the philanthropic efforts of ALSAC, underscoring the critical role of sustained funding in enabling transformative pediatric oncology research. Continued investment in longitudinal survivor cohorts and genomic technologies promises to deepen our understanding of therapy late effects and inherited risks, ultimately informing innovations in both treatment approaches and survivorship care.

In sum, this study represents a significant advancement in recognizing the intertwined contributions of genetics and cancer therapy to the risk of secondary malignancies in childhood cancer survivors. By quantifying these factors at the population level, it lays the groundwork for more individualized, genetically informed surveillance strategies, heralding a new era in survivorship medicine. As survivorship rates improve worldwide, addressing secondary health risks with precision will be vital to ensuring that these patients not only survive but thrive in the decades following their initial cancer battle.

Subject of Research: Contributions of cancer treatment and genetic predisposition to secondary cancer risk in long-term survivors of childhood cancer

Article Title: Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St. Jude Lifetime Cohort and the Childhood Cancer Survivor Study

News Publication Date: 28-May-2025

Web References:

• St. Jude Lifetime Cohort Study: https://sjlife.stjude.org/
• St. Jude Children’s Research Hospital: https://www.stjude.org/

Image Credits: St. Jude Children’s Research Hospital

Keywords: Cancer genomics, secondary cancers, childhood cancer survivorship, polygenic risk score, radiation therapy late effects, chemotherapy late effects, genetic predisposition, pediatric oncology, secondary neoplasms, personalized medicine